These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3806925)

  • 1. Diagnostic and therapeutic technology assessment. Bacillus Calmette-Guerin immunotherapy in bladder cancer.
    JAMA; 1987 Mar; 257(9):1238-40. PubMed ID: 3806925
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic and therapeutic technology assessment. BCG immunotherapy in bladder cancer: a reassessment.
    JAMA; 1988 Apr; 259(14):2153-5. PubMed ID: 3346993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Miliary tuberculosis of the lung in a patient treated with bacillus Calmette-Guerin for superficial bladder cancer.
    Iantorno R; Nicolai M; Storto ML; Ciccotosto C; Cipollone G; Mastroprimiano G; Tenaglia RL
    J Urol; 1998 May; 159(5):1639-40. PubMed ID: 9554372
    [No Abstract]   [Full Text] [Related]  

  • 4. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
    Sosnowski JT
    Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
    Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
    J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guerin immunotherapy of infiltrating bladder cancer.
    Netto NR; Lemos GC
    J Urol; 1984 Oct; 132(4):675-7. PubMed ID: 6471211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
    Miyazaki J; Onozawa M; Takaoka E; Yano I
    Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
    Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
    J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
    [No Abstract]   [Full Text] [Related]  

  • 10. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
    Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
    South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
    Lamm DL
    Nihon Hinyokika Gakkai Zasshi; 1995 Jan; 86(1):9-10. PubMed ID: 7897925
    [No Abstract]   [Full Text] [Related]  

  • 12. A six-week course of bacillus Calmette-Guérin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53.
    Oh JJ; Ji SH; Choi DK; Gong IH; Kim TH; Park DS
    Oncology; 2010; 79(5-6):440-6. PubMed ID: 21487231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Noor MA; Biyabani SR; Burney IA; Talatia J
    J Pak Med Assoc; 2002 Dec; 52(12):578-80. PubMed ID: 12627909
    [No Abstract]   [Full Text] [Related]  

  • 14. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive arthritis associated with Bacillus Calmette-Guerin immunotherapy for carcinoma of the bladder: a report of two cases.
    Jawad AS; Kahn L; Copland RF; Henderson DC; Abdul-Ahad AK
    Br J Rheumatol; 1993 Nov; 32(11):1018-20. PubMed ID: 8220923
    [No Abstract]   [Full Text] [Related]  

  • 16. Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response.
    Bui TT; Schellhammer PF
    Urology; 1997 May; 49(5):687-90; discussion 690-1. PubMed ID: 9145971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting bacillus Calmette-Guerin immunotherapy effectiveness.
    Griffith TS
    J Urol; 2007 Dec; 178(6):2247-8. PubMed ID: 17936825
    [No Abstract]   [Full Text] [Related]  

  • 18. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCG in bladder cancer--a warning.
    Nicol D
    Aust N Z J Med; 1995 Aug; 25(4):275-7. PubMed ID: 8540864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.